CA-ASM-GLOBAL
10.10.2023 15:01:28 CEST | Business Wire | Press release
Highlighted by its leading role in helping guide three landmark Puerto Rico venues to a just-concluded record-breaking 2023 financial performance, ASM Global has been signed to a long-term renewal contract continuing its two-decade strategic and operational role with those properties.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004634675/en/
Puerto Rico Convention Center (Photo: Business Wire)
The Coliseo de Puerto Rico José Miguel Agrelot, located at the Golden Mile of the island capital of San Juan, is the biggest indoor arena in Puerto Rico dedicated to entertainment. Dedicated in 2004 with a performance by Van Halen, it accommodates up to 18,500 spectators.
Antiguo Casino de Puerto Rico is a historic Beaux-Arts architecture-style building dating from 1917, featuring spectacular verdant gardens, balconies, white marble floors and an iconic swirling grand central staircase and is on the national Register of Historic Places.
The Puerto Rico Convention Center is the largest convention center in the Caribbean and one of the most technologically advanced in the Americas. It features more than 600,000 square feet for multiuse events, meetings, conferences and exhibitions and is renowned for its design and the functionality of its spaces that can accommodate up to 25,000 visitors simultaneously.
The continuing success of these three venues reflects ASM Global’s collaboration with the government to elevate the island beyond its fame as simply a collection of beautiful beaches to one of the world’s great entertainment destinations.
ASM Global President and CEO Ron Bension said, “We’re incredibly proud to work with a client as visionary as the Puerto Rico Convention Center District Authority. Its determination to position Puerto Rico at the forefront of the industry is admirable. It continues to be a pleasure to play a role in executing a plan to highlight the many attributes that the island has and what these wonderful venues have to offer.”
The executive director of the Puerto Rico Convention Center District Authority, Mrs. Mariela Vallines, said, “Our partnership with ASM Global has been fundamental in crafting and implementing a successful promotional, marketing and operational strategy that has yielded consistent growth in creating awareness of Puerto Rico as the ideal destination for conventions, meetings and a wide array of premium special events, thus helping foster the island’s tourism efforts as well.
“As business partners, ASM Global has ensured first-class service and facilities offering, expanding traffic and incremental record-breaking revenues for the Puerto Rico Convention District properties over the years. Their world-class management expertise and team have been key in achieving unsurpassed business objectives that have garnered multiple global industry recognitions for Puerto Rico and ASM Global. We look forward to this continued partnership and collaborative alliance to reach event higher milestones for our convention district and for Puerto Rico’s economic development.”
Jorge L. Pérez, CVE, regional general manager for ASM Global, said, “Coliseo de Puerto Rico is one of the world’s most profitable arenas and has been featured and consistently ranks among the top 15 in ticket sales globally. Similarly, the Puerto Rico Convention District has been the recipient of multiple accolades for and distinctive achievement awards for its overall excellence. Overall, our premier properties on the island have welcomed 20 million visitors since opening; and we look forward to the continuation of this partnership. ASM Global is committed with the Puerto Rico Convention Center District Authority as strategic partners in the expansion and continued success of our Puerto Rico’s award-winning venues and convention facilities.”
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Follow us on Facebook, Instagram, Twitter and LinkedIn, or visit asmglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231004634675/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom